ArticleiScience2026
The use of multi-species probiotic-derived vesicles to encapsulate luteolin for preventing colitis in a mouse model.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotic-derived membrane vesicles (MVs) offer advantages over live probiotics, including lower immunogenicity and enhanced bioavailability of dietary compounds. However, their composition and function depend on culture conditions. In this study, MVs from a single probiotic strain (S-MVs) were compared with those from co-cultured multi-species probiotics (M-MVs). M-MVs showed superior radical scavenging ability due to characteristic antioxidant proteins. Luteolin (Lut), a hydrophobic flavonoid, was loaded into M-MVs to generate Lut-MVs. Compared with Lut or M-MVs alone, Lut-MVs had enhanced water solubility, gastrointestinal stability, and antioxidative capacity. In a dextran sulfate sodium (DSS)-induced mouse colitis model, Lut-MVs prevented colitis by alleviating oxidative damage, improving intestinal barrier function, reducing inflammatory responses, and regulating colonic microbial balance. This work provides a method for preparing probiotic-derived vesicles and highlights their potential as carriers for hydrophobic drugs in treating colon diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.